Status:
COMPLETED
Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C
Lead Sponsor:
Hospital Clinic of Barcelona
Conditions:
Chronic Hepatitis C
Liver Fibrosis
Eligibility:
All Genders
35-65 years
Phase:
PHASE4
Brief Summary
There is evidence on the beneficial effects of the administration of angiotensin II type 1 (AT1) receptors antagonists on liver fibrosis in hepatic stellate cells, experimental models of liver fibrosi...
Eligibility Criteria
Inclusion
- age between 35 and 65 years
- chronic hepatitis C with intermediate fibrosis (F2-F3 in Metavir score).
- non-responder or contraindication to antiviral therapy.
Exclusion
- any other cause of liver disease
- HIV positive
- alcohol consumption
- arterial hypertension
- creatinine \> 1.5mg/dL
- treatment with AT1 receptor antagonists or angiotensin converting enzyme inhibitors in the past 12 months.
- antiviral therapy in the past 12 months
- contraindications to oral losartan
Key Trial Info
Start Date :
March 1 2003
Trial Type :
INTERVENTIONAL
End Date :
January 1 2006
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00298714
Start Date
March 1 2003
End Date
January 1 2006
Last Update
November 22 2007
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.